Manidipina Zentiva

Manidipine, the active ingredient in Manidipina Zentiva, is a calcium channel blocker (dihydropyridine) presented as a tablet for oral use. It is employed to treat essential hypertension in adult patients.

GNH USA supplies Manidipina Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manidipina Zentiva is a calcium‑channel‑blocking antihypertensive used to manage elevated blood pressure. - Essential hypertension: lowers systolic and diastolic pressure to target levels. - Primary hypertension: assists in achieving recommended blood pressure control. - Elevated blood pressure: contributes to overall cardiovascular risk reduction.

Manidipina Zentiva may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the lower limbs. - Dizziness or light‑headedness. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Allergic reaction: rash, itching, or swelling. - Angioedema: swelling of face, lips, or throat. - Hepatic injury: abnormal liver function tests. - Cardiac conduction abnormalities: heart block or arrhythmias.

Before initiating therapy, consider the following safety measures. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Hepatic impairment: use with caution and adjust if necessary. - Concomitant antihypertensives: monitor for additive hypotensive effects. - Cardiovascular disease: assess risk of reflex tachycardia. - Abrupt discontinuation: taper to prevent rebound hypertension. - Store at below 25°C: keep in the original pack, protect from moisture.

Manidipina Zentiva can interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - Other calcium‑channel blockers: additive vasodilatory effect. - Grapefruit juice: can raise drug concentration. - Concurrent antihypertensives: risk of severe hypotension. - Rifampicin: may reduce efficacy by inducing metabolism.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood pressure lowering. - Beta‑blockers: monitor heart rate and blood pressure. - NSAIDs: may blunt antihypertensive response. - ACE inhibitors or ARBs: watch for renal function changes. - Lipid‑lowering agents (e.g., statins): potential CYP3A4 competition.